Ardelyx Inc
NASDAQ:ARDX
Intrinsic Value
Ardelyx, Inc. is a biopharmaceutical company. [ Read More ]
The intrinsic value of one ARDX stock under the Base Case scenario is 13.63 USD. Compared to the current market price of 6.43 USD, Ardelyx Inc is Undervalued by 53%.
Valuation Backtest
Ardelyx Inc
Run backtest to discover the historical profit from buying and selling ARDX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Ardelyx Inc
Current Assets | 246.1m |
Cash & Short-Term Investments | 184.3m |
Receivables | 22m |
Other Current Assets | 39.8m |
Non-Current Assets | 51.5m |
PP&E | 6.6m |
Other Non-Current Assets | 44.9m |
Current Liabilities | 50.4m |
Accounts Payable | 11.1m |
Accrued Liabilities | 30m |
Other Current Liabilities | 9.2m |
Non-Current Liabilities | 80.4m |
Long-Term Debt | 49.8m |
Other Non-Current Liabilities | 30.5m |
Earnings Waterfall
Ardelyx Inc
Revenue
|
124.5m
USD
|
Cost of Revenue
|
-17.8m
USD
|
Gross Profit
|
106.7m
USD
|
Operating Expenses
|
-169.9m
USD
|
Operating Income
|
-63.3m
USD
|
Other Expenses
|
-2.8m
USD
|
Net Income
|
-66.1m
USD
|
Free Cash Flow Analysis
Ardelyx Inc
ARDX Profitability Score
Profitability Due Diligence
Ardelyx Inc's profitability score is 38/100. The higher the profitability score, the more profitable the company is.
Score
Ardelyx Inc's profitability score is 38/100. The higher the profitability score, the more profitable the company is.
ARDX Solvency Score
Solvency Due Diligence
Ardelyx Inc's solvency score is 58/100. The higher the solvency score, the more solvent the company is.
Score
Ardelyx Inc's solvency score is 58/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ARDX Price Targets Summary
Ardelyx Inc
According to Wall Street analysts, the average 1-year price target for ARDX is 13.66 USD with a low forecast of 11.11 USD and a high forecast of 16.8 USD.
Ownership
ARDX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ARDX Price
Ardelyx Inc
Average Annual Return | 38.7% |
Standard Deviation of Annual Returns | 102.85% |
Max Drawdown | -94% |
Market Capitalization | 1.5B USD |
Shares Outstanding | 232 690 000 |
Percentage of Shares Shorted | 15.3% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Ardelyx, Inc. is a biopharmaceutical company. The company is headquartered in Fremont, California and currently employs 86 full-time employees. The company went IPO on 2014-06-19. The firm focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. The firm's product pipeline includes IBSRELA (tenapanor), XPHOZAH, RDX013 Program, and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of hyperphosphatemia, a condition of elevated levels of phosphate in the blood, common among patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.
Contact
IPO
Employees
Officers
The intrinsic value of one ARDX stock under the Base Case scenario is 13.63 USD.
Compared to the current market price of 6.43 USD, Ardelyx Inc is Undervalued by 53%.